Quick Takeaways:
- IDEXX Laboratories launched Catalyst proBNP, the first and only dual-species, in-clinic test for NT-proBNP in cats and dogs. The test brings quantitative cardiac assessment to the point of care, delivering results in minutes.
- Available on the Catalyst platform with nearly 80,000 analyzers globally, Catalyst proBNP supports screening, diagnosis and monitoring of heart disease. It can help identify subclinical disease, support preoperative assessments and distinguish cardiac from noncardiac causes of respiratory distress.
- Results integrate into VetConnect PLUS alongside patient history and built-in interpretation guidance, helping veterinarians make faster decisions and determine when monitoring or specialist referral is needed. The test launches in North America in October 2026, followed by international markets.
Why It Matters?
IDEXX’s Catalyst proBNP brings a well‑known heart‑disease blood test into the vet clinic with results in minutes, so vets can spot hidden heart problems, decide quickly in breathing emergencies, and monitor patients without waiting days for a lab. Because it runs on IDEXX’s widely installed Catalyst analyzers and feeds results into VetConnect PLUS with interpretation guidance, it can increase early detection of feline and canine heart disease, reduce unnecessary referrals, and expand access to cardiac testing in general practice, especially where specialist care is limited.
Source: Businesswire
